These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 20639561

  • 1. Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients.
    Cooper CJ, Metch B, Dragavon J, Coombs RW, Baden LR, NIAID HIV Vaccine Trials Network (HVTN) Vaccine-Induced Seropositivity (VISP) Task Force.
    JAMA; 2010 Jul 21; 304(3):275-83. PubMed ID: 20639561
    [Abstract] [Full Text] [Related]

  • 2. Frequency of human immunodeficiency virus (HIV) infection among contemporary anti-HIV-1 and anti-HIV-1/2 supplemental test-indeterminate blood donors. The Retrovirus Epidemiology Donor Study.
    Busch MP, Kleinman SH, Williams AE, Smith JW, Ownby HE, Laycock ME, Lee LL, Pau CP, Schreiber GB.
    Transfusion; 1996 Jan 21; 36(1):37-44. PubMed ID: 8607151
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. HIV seroconversion without infection after receipt of adenovirus-vectored HIV type 1 vaccine.
    Quirk EK, Mogg R, Brown DD, Lally MA, Mehrotra DV, DiNubile MJ, Robertson MN.
    Clin Infect Dis; 2008 Dec 15; 47(12):1593-9. PubMed ID: 18990058
    [Abstract] [Full Text] [Related]

  • 5. Cross-protocol assessment of induction and durability of VISP/R in HIV preventive vaccine trial participants.
    Espy N, Han X, Grant S, Kwara E, Lakshminarayanan B, Stirewalt M, Seaton KE, Tomaras GD, Goecker E, McElrath J, Andriesen J, Huang Y, Walsh SR, Hural J.
    PLOS Glob Public Health; 2023 Dec 15; 3(6):e0002037. PubMed ID: 37289667
    [Abstract] [Full Text] [Related]

  • 6. Exploring a community's understanding of HIV vaccine‑induced seropositivity in a South African research setting.
    Malahleha M, Dilraj A, Jean J, Morar NS, Dietrich JJ, Ross M, Mbatsane E, Keefer MC, Ahmed K.
    S Afr Med J; 2022 Dec 20; 113(1):36-41. PubMed ID: 36537546
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of epidemiological and serological predictors of human immunodeficiency virus type-1 (HIV-1) infection among high risk professional blood donors with western blot indeterminate results.
    Chattopadhya D, Aggarwal RK, Baveja UK, Doda V, Kumari S.
    J Clin Virol; 1998 Jul 24; 11(1):39-49. PubMed ID: 9784142
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Evaluation of a system using oral mucosal transudate for HIV-1 antibody screening and confirmatory testing. OraSure HIV Clinical Trials Group.
    Gallo D, George JR, Fitchen JH, Goldstein AS, Hindahl MS.
    JAMA; 1997 Jan 15; 277(3):254-8. PubMed ID: 9005276
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
    Bekker LG, Moodie Z, Grunenberg N, Laher F, Tomaras GD, Cohen KW, Allen M, Malahleha M, Mngadi K, Daniels B, Innes C, Bentley C, Frahm N, Morris DE, Morris L, Mkhize NN, Montefiori DC, Sarzotti-Kelsoe M, Grant S, Yu C, Mehra VL, Pensiero MN, Phogat S, DiazGranados CA, Barnett SW, Kanesa-Thasan N, Koutsoukos M, Michael NL, Robb ML, Kublin JG, Gilbert PB, Corey L, Gray GE, McElrath MJ, HVTN 100 Protocol Team.
    Lancet HIV; 2018 Jul 15; 5(7):e366-e378. PubMed ID: 29898870
    [Abstract] [Full Text] [Related]

  • 14. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22).
    Stephenson KE, Wegmann F, Tomaka F, Walsh SR, Tan CS, Lavreys L, Ansel JL, Kanjilal DG, Jaegle K, Nkolola JP, Peter L, Fogel R, Bradshaw C, Tyler A, Makoni T, Howe L, Quijada D, Chandrashekar A, Bondzie EA, Borducchi EN, Yanosick KE, Hendriks J, Nijs S, Truyers C, Tolboom J, Zahn RC, Seaman MS, Alter G, Stieh DJ, Pau MG, Schuitemaker H, Barouch DH.
    Lancet HIV; 2020 Jun 15; 7(6):e410-e421. PubMed ID: 32078815
    [Abstract] [Full Text] [Related]

  • 15. Utility of various commercially available human immunodeficiency virus (HIV) antibody diagnostic kits for use in conjunction with efficacy trials of HIV-1 vaccines.
    Schwartz DH, Mazumdar A, Winston S, Harkonen S.
    Clin Diagn Lab Immunol; 1995 May 15; 2(3):268-71. PubMed ID: 7664169
    [Abstract] [Full Text] [Related]

  • 16. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
    Nyombayire J, Anzala O, Gazzard B, Karita E, Bergin P, Hayes P, Kopycinski J, Omosa-Manyonyi G, Jackson A, Bizimana J, Farah B, Sayeed E, Parks CL, Inoue M, Hironaka T, Hara H, Shu T, Matano T, Dally L, Barin B, Park H, Gilmour J, Lombardo A, Excler JL, Fast P, Laufer DS, Cox JH, S001 Study Team.
    J Infect Dis; 2017 Jan 01; 215(1):95-104. PubMed ID: 28077588
    [Abstract] [Full Text] [Related]

  • 17. Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network.
    Keefer MC, Graham BS, Belshe RB, Schwartz D, Corey L, Bolognesi DP, Stablein DM, Montefiori DC, McElrath MJ, Clements ML.
    AIDS Res Hum Retroviruses; 1994 Dec 01; 10(12):1713-23. PubMed ID: 7888231
    [Abstract] [Full Text] [Related]

  • 18. Persistently negative HIV-1 antibody enzyme immunoassay screening results for patients with HIV-1 infection and AIDS: serologic, clinical, and virologic results. Seronegative AIDS Clinical Study Group.
    Sullivan PS, Schable C, Koch W, Do AN, Spira T, Lansky A, Ellenberger D, Lal RB, Hyer C, Davis R, Marx M, Paul S, Kent J, Armor R, McFarland J, Lafontaine J, Mottice S, Cassol SA, Michael N.
    AIDS; 1999 Jan 14; 13(1):89-96. PubMed ID: 10207549
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.